”I think it could be impactful,” Cuban told Fortune in an email. “Their challenge is going to be who has more power and influence over the industry, the PBMs/insurance companies and the contracts they have with brand manufacturers, or the President. That has not been determined yet.”
“So until these fundamental issues change, it’s going to be difficult to truly impact pricing for all patients,” Cuban said.
“Most Americans buy drugs through their insurance plan, so that would mainly help the uninsured,” Altman said.
